Atypical Parkinsonism: What Is the Life Expectancy?

Most people diagnosed with an atypical parkinsonian syndrome live roughly five to ten years from the onset of symptoms, though the range varies considerably depending on which condition is involved and how quickly it progresses. That is noticeably shorter than Parkinson’s disease itself, where five-year survival sits around 64%, compared with roughly 30% for the most aggressive atypical form, progressive supranuclear palsy.¹ The term “atypical parkinsonism” covers several distinct diseases, each with its own trajectory, and understanding which one you’re dealing with matters enormously for planning ahead.

What Counts as Atypical Parkinsonism

Atypical parkinsonian syndromes share some features with Parkinson’s disease, such as stiffness, slowness of movement, and balance problems, but they follow a different course and respond poorly or not at all to levodopa, the main Parkinson’s medication. The four conditions most commonly grouped under this label are progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal degeneration (CBD), and dementia with Lewy bodies (DLB). Each has a distinct pattern of brain damage and a somewhat different expected survival. A large population-based study spanning over 360 million person-years of observation confirmed that all four carry significantly worse survival than Parkinson’s disease.¹

Progressive Supranuclear Palsy

PSP tends to have the most aggressive course among the atypical syndromes. Mean survival from symptom onset is about eight years, though the spread is wide, with some individuals living well beyond a decade and others declining within four or five years.² Five-year survival is around 30%, the lowest of the degenerative parkinsonisms tracked in population data.¹ The hallmark early feature is backward falls, often within the first year, and the disease eventually impairs eye movements, speech, and swallowing.

What seems to matter most for how long someone with PSP survives is whether dementia is present at diagnosis. In one cohort study, dementia at the time of diagnosis was the only factor linked to a shorter life expectancy; sex, age at onset, education, and the severity of movement symptoms did not correlate with survival.² Brain imaging research has confirmed that the degree of shrinkage in specific brain regions, particularly the striatum, cerebellum, and frontal cortex, tracks with how far along a person is in their disease course, raising the possibility that MRI scans could eventually help predict how fast someone will decline.³

PSP also comes in several clinical variants. The classic form, sometimes called Richardson syndrome, progresses fastest. Other variants that look more like Parkinson’s disease at the start may progress more slowly, though they eventually converge on a similar picture. When studies adjust for disease severity, PSP patients as a group still have a worse prognosis than MSA patients at the same stage of disability.⁴

Multiple System Atrophy

MSA has two main subtypes. In one (MSA-P), parkinsonism dominates; in the other (MSA-C), balance and coordination problems from cerebellar damage are the leading feature. Despite their different presentations, median survival is similar for both, around nine years from symptom onset.⁵ Some older estimates put the average closer to seven years, and the usual range quoted across studies is five to ten years.⁶

A distinctive feature of MSA is autonomic dysfunction: problems with blood pressure regulation, bladder control, and other functions the nervous system handles automatically. How early those autonomic problems appear turns out to be an important signal. People in whom severe cardiovascular autonomic failure and urinary problems develop late, roughly nine or more years after other symptoms appear, tend to survive considerably longer than those who develop those issues early.⁷ That finding holds regardless of whether the person has the parkinsonism-dominant or cerebellar-dominant subtype.

MSA also carries a specific mortality risk from sudden cardiac arrest, which sets it apart from the other atypical syndromes where respiratory infections are the primary killer.⁸ The cardiovascular instability linked to autonomic failure is thought to be responsible.

Corticobasal Degeneration

CBD is the rarest of the atypical parkinsonisms and among the hardest to diagnose during life. Median survival from symptom onset is roughly seven to eight years across studies. One autopsy-confirmed series found a median of 7.9 years, with a range stretching from about two and a half to twelve and a half years.⁹ A larger and more recent study of pathologically confirmed cases reported a median of seven years and mapped out the typical sequence of milestones: gait difficulty tends to come first, followed within two years by falls and cognitive impairment, and then speech problems, difficulty looking up or down, and bladder issues. Swallowing difficulty, which raises the risk of pneumonia, typically appears around five years in.¹⁰

Knowing that timeline can be genuinely useful for families. If a person with CBD is three years from symptom onset and has not yet developed significant swallowing trouble, that milestone is still a couple of years away on average. That means there is time to have conversations about feeding preferences, mobility support, and advance care planning before the situation becomes urgent.

Dementia with Lewy Bodies

DLB is sometimes classified with the dementias rather than with parkinsonism, but it shares enough biology with Parkinson’s disease, specifically the buildup of the protein alpha-synuclein in the brain, that it often falls under the atypical parkinsonism umbrella. Average survival from diagnosis is about four years, compared with roughly five and a half years for Alzheimer’s disease, a difference of over a year and a half.¹¹ Measured from the onset of dementia symptoms rather than from formal diagnosis, survival is closer to seven years, because there is often a lag between when symptoms begin and when the diagnosis is made.¹²

A systematic review and meta-analysis comparing different dementia types found that Lewy body dementia carried the highest risk of death relative to people without dementia, followed by frontotemporal degeneration, vascular dementia, and then Alzheimer’s disease.¹³ The shorter survival in DLB is not explained by differences in age, sex, or baseline cognitive scores. It appears to be something about the disease process itself.

Why People with Atypical Parkinsonism Die

Across all the atypical syndromes, the leading cause of death is respiratory infection, specifically aspiration pneumonia.⁸ As swallowing muscles weaken, food or saliva is inhaled into the lungs, leading to infection. Dysphagia, the clinical term for swallowing difficulty, occurs in all of these conditions and also contributes to malnutrition and weight loss, which compounds the decline.¹⁴

Falls are another major contributor to morbidity and mortality, especially in PSP, where backward falls are frequent and often start early in the disease.¹⁵ Hip fractures and head injuries from falls can trigger a cascade of immobility, hospitalization, and infection that shortens life. In MSA, sudden cardiac arrest is an additional and sometimes underappreciated risk, driven by the breakdown of the autonomic nervous system’s control over heart rhythm.⁸

What Predicts a Longer or Shorter Course

Two factors show up repeatedly across studies as the strongest predictors of survival in parkinsonism: age at symptom onset and the presence or absence of cognitive impairment. Younger onset tends to mean more years of life remaining, and people without cognitive decline can have a survival that approaches normal life expectancy, even with a parkinsonian diagnosis.¹⁶ That finding is striking because it highlights how much of the shortened survival in parkinsonism is driven by the cognitive side of the disease, not just the movement problems.

The speed of progression also matters. In a large clinical trial involving PSP and MSA patients, investigators found that people who had reached the same level of disability in a shorter time, so-called fast progressors, had a worse prognosis than those who reached the same disability level more slowly.⁴ Scales measuring daily-life independence and overall disease severity were the strongest predictors of survival, more so than any single symptom.

For parkinsonism broadly, a population study estimated that at age 65, having a parkinsonian condition reduced life expectancy by about seven years compared to controls. At age 85, though, the gap narrowed to roughly one year, a difference that was no longer statistically clear.¹⁷ The practical takeaway: a diagnosis at a younger age carries a larger penalty in absolute years lost, while a diagnosis in very old age may have a smaller relative impact because competing causes of death catch up.

Blood Tests That May Help Predict Outcomes

Researchers have been hunting for a simple blood or spinal fluid marker that could help predict how fast someone with atypical parkinsonism will decline. The leading candidate right now is neurofilament light chain (NfL), a protein released into the bloodstream when nerve cells are damaged. Levels of NfL are markedly higher in people with MSA and PSP compared with Parkinson’s disease, and those levels correlate with disease severity, brain shrinkage, and survival.¹⁸

In one study measuring NfL in spinal fluid, higher levels were associated with an increased risk of death across the board: in Parkinson’s disease combined with MSA, in PSP on its own, and in the overall cohort of people with parkinsonism.¹⁹ NfL is not yet used routinely in clinical practice for prognosis, but it is increasingly measured in research settings and could become part of standard workups in the coming years. Its value is not just in prediction; if clinical trials for new therapies need to identify fast progressors who stand to benefit most, NfL could help select the right participants.

Feeding Tubes and Late-Stage Decisions

When swallowing deteriorates, families and clinicians face a difficult question: whether to place a feeding tube. In atypical parkinsonism, the evidence on gastrostomy is sparse and sobering. A retrospective study of parkinsonism patients who received feeding tubes found a median survival of about six months after the procedure, and pneumonia remained the most frequent complication even with tube feeding.²⁰ People who were already totally dependent at the time of tube placement fared the worst. A national UK survey of clinicians found widespread uncertainty about recommending gastrostomy in atypical parkinsonism, with many citing insufficient evidence on whether it actually prolongs life or improves quality of life.²¹

This does not mean feeding tubes are never appropriate, but it does mean the decision should be made carefully and early enough that the person can participate. A tube placed when someone still has some independence and can tolerate the procedure is a different scenario from one placed in crisis during an acute aspiration event.

Interdisciplinary Care and What It Can Change

There are no disease-modifying treatments for any of the atypical parkinsonian syndromes. No drug has been shown to slow the underlying neurodegeneration. That makes the question of life expectancy feel especially bleak, but it understates how much supportive care can do. An interdisciplinary care model, one that brings together neurologists, physiotherapists, speech therapists, palliative care specialists, and social workers, has been shown to improve symptom burden, quality of life, and engagement with advance care planning in neurodegenerative conditions.²²

Palliative care in this context does not mean giving up. It means managing pain, breathlessness, anxiety, depression, and sleep disturbance while helping families plan for what is ahead. Speech therapy can extend the period during which someone eats safely by mouth. Physiotherapy can reduce the frequency and severity of falls. Occupational therapy can keep someone functioning at home longer. These interventions are unlikely to change the median survival numbers quoted above by years, but they can meaningfully change how those years are lived.

When the Diagnosis Itself Is Uncertain

One complication that hangs over every survival statistic is diagnostic accuracy. Atypical parkinsonian syndromes are notoriously difficult to distinguish from one another, and from Parkinson’s disease itself, especially in the first few years. Only about half of pathologically confirmed CBD cases were recognized as such during life.¹⁰ PSP is somewhat better recognized but still frequently misdiagnosed early on, and the same is true for MSA.

This matters for survival estimates in two ways. First, the numbers quoted from autopsy-confirmed studies are more reliable but smaller, while the numbers from clinical cohorts are larger but contaminated with misdiagnoses. Second, and more practically, if you or someone you care about has been given one of these diagnoses, there is a real chance the diagnosis will be revised as the disease evolves. A revision from, say, suspected Parkinson’s disease to PSP changes the expected timeline substantially. It also changes which complications to watch for and which supportive therapies to prioritize. If the clinical picture does not match the original diagnosis after a year or two, asking the neurologist to reconsider is reasonable and sometimes necessary.

Sex Differences and Demographics

Unlike Parkinson’s disease, which is more common in men, the sex distribution across atypical parkinsonian syndromes is roughly even, with a slight female predominance reported in CBD.⁸ For DLB, male sex and the presence of a particular genetic variant (the APOE ε4 allele, better known for its link to Alzheimer’s risk) have been associated with modestly increased mortality.¹² For PSP and MSA, sex has not emerged as a consistent predictor of how long someone will survive. Most of the variation in prognosis appears to be driven by the disease subtype, the speed of progression, and whether cognitive decline is part of the picture.

1
PubMed Central. Comparative Analysis of the Incidence, Prevalence, and Survival of 8 Types of Parkinsonism in a Population-Based Study with 367 Million Person Years of Observation over 21 Years
2
PubMed. Natural history and predictors of survival in progressive supranuclear palsy
3
PubMed Central. Structural correlates of survival in progressive supranuclear palsy
4
Brain. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS Study
5
PubMed Central. Multiple System Atrophy: Prognostic Indicators of Survival
6
Oxford Academic. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS Study
7
PubMed. Multiple system atrophy with prolonged survival: is late onset of dysautonomia the clue?
8
PubMed Central. Epidemiology of atypical parkinsonian syndromes
9
PubMed Central. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination
10
Brain Communications. Clinical course of pathologically confirmed corticobasal degeneration and corticobasal syndrome
11
PubMed. Survival time and differences between dementia with Lewy bodies and Alzheimer’s disease following diagnosis: A meta-analysis of longitudinal studies
12
PubMed. Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease
13
The Lancet Healthy Longevity. Mortality rates in Alzheimer’s disease and non-Alzheimer’s dementias: a systematic review and meta-analysis
14
Age and Ageing. Percutaneous endoscopic gastrostomy in atypical Parkinsonian syndromes: survival and aspiration risk in an international cohort
15
Parkinsonism & Related Disorders. Understanding falls in progressive supranuclear palsy
16
npj Parkinson’s Disease. Factors associated with mortality in early stages of parkinsonism
17
Parkinsonism & Related Disorders. Life expectancy of parkinsonism patients in the general population
18
PubMed. Neurofilament light chain as a diagnostic and prognostic biomarker in atypical parkinsonisms: current evidence, new data, challenges, and future directions
19
PubMed. Cerebrospinal fluid neurofilament light and tau protein as mortality biomarkers in parkinsonism
20
PubMed. Outcome of gastrostomy in parkinsonism: A retrospective study
21
PubMed Central. Clinical Practices and Opinions toward Gastrostomy Use in Patients with Atypical Parkinsonian Syndromes: A National Survey in the UK
22
PubMed. Neurological update: the palliative care landscape for atypical parkinsonian syndromes